Feinberg School of Medicine

Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results

Retrieved on: 
Thursday, March 28, 2024
Q&A, Exercise, Patient, Pulmonary hypertension, Cardiovascular Research, Clinical trial, IP, Therapy, LINK, Research, Science, LEVEL, Public expenditure, Heart failure, Development, Tenax, Disease, KOL, TNX-102, First, Research and development, MPH, Cardiology, Conference, Patent, Doctor of Philosophy, Faculty, MBA, Levosimendan, THT, Feinberg School of Medicine, Pharmaceutical industry

We also made important progress in further expanding levosimendan’s U.S. intellectual property protections, securing the future commercial value of TNX-103.

Key Points: 
  • We also made important progress in further expanding levosimendan’s U.S. intellectual property protections, securing the future commercial value of TNX-103.
  • In February 2024, Tenax Therapeutics announced that the first patient had enrolled in the Phase 3 LEVEL Study (LEVosimendan to Improve Exercise Limitation in PH-HFpEF Patients) ( NCT05983250 ).
  • LINK TO REGISTER
    Tenax Therapeutics reported cash and cash equivalents of $9.8 million as of December 31, 2023.
  • Tenax Therapeutics reported a net loss for 2023 of $7.7 million, compared to a net loss of $11.0 million in 2022.

Plus Therapeutics Announces Validation & Clinical Implementation of CSF-01 Leptomeningeal Cancer Cell Diagnostic

Retrieved on: 
Monday, March 25, 2024
Diagnosis, Certification, LM, Plus Therapeutics, NSCLC, CSF, Partnership, Central nervous system, Patient, CNS, Breast, PSTV, Lung cancer, Clinical trial, Therapy, Cancer, Rhenium, CLIA, Research institute, Cancer prevention, Feinberg School of Medicine, Associate professor

AUSTIN, Texas, March 25, 2024 (GLOBE NEWSWIRE) --  Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced it has successfully completed key validation testing and implementation of its tumor cell enumeration assay, known as CSF-01, to be used initially as an exploratory endpoint in its ReSPECT-LM clinical trials.

Key Points: 
  • “In mid-2023, the Company licensed CSF-01, as well as a broader CSF diagnostic testing portfolio due to high conviction that routine implementation will substantially improve diagnosis and clinical management of LM,” said Marc H. Hedrick, M.D., President & CEO of Plus Therapeutics.
  • While validated for use in Plus’ clinical development programs, full Clinical Laboratory Improvement Amendments (CLIA) certification is not anticipated until 2025.
  • The ReSPECT-LM trial, including support for CSF-01 testing, is currently receiving grant funding from the Cancer Prevention and Research Institute of Texas (CPRIT).
  • If the FORSEE data is positive, we intend to work toward increasing commercial reimbursement for the CLIA-certified test and explore partnerships to maximize diagnostic utilization for the broader CNS cancer space.

CHICAGO RIVER SWIM TO MAKE HISTORY AS FIRST OPEN WATER EVENT IN NEARLY 100 YEARS

Retrieved on: 
Wednesday, April 3, 2024
Clark Street Bridge, Dearborn Street, Metropolitan, ALS, Safety, Research, Northwestern University, Water quality, Chicago River, Feinberg School of Medicine, State Street

CHICAGO, April 3, 2024 /PRNewswire/ -- The inaugural Chicago River Swim marks a historic revival of open water swimming in downtown Chicago, celebrating the river's transformation and supporting ALS research.

Key Points: 
  • CHICAGO, April 3, 2024 /PRNewswire/ -- The inaugural Chicago River Swim marks a historic revival of open water swimming in downtown Chicago, celebrating the river's transformation and supporting ALS research.
  • We are committed to conducting a safe event, backed by the latest in water quality technology and a thorough safety plan."
  • Chicago River Swim will use this combined data to determine if the water meets regulatory standards for human contact.
  • Proceeds from the Chicago River Swim will also support local learn-to-swim programs for at-risk youth.

Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024

Retrieved on: 
Thursday, February 29, 2024
Research, Pulmonary hypertension, Conference, Heart failure, Therapy, Patient, Feinberg School of Medicine, THT, Pharmaceutical industry

CHAPEL HILL, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced Dr. Sanjiv Shah, Stone Endowed Professor of Medicine, Director of Research for the Bluhm Cardiovascular Institute, and Director of the HFpEF Program at Northwestern University Feinberg School of Medicine, will present data and review the scientific basis for the use of levosimendan in PH-HFpEF. Dr Shah’s presentation will occur during a scientific session focused on the treatment of pulmonary hypertension in patients with heart failure at the upcoming Cardiovascular Research Foundation’s Technology and Heart Failure Therapeutics (THT) Conference in Boston.

Key Points: 
  • Dr. Sanjiv Shah, a renowned, global expert in the treatment of HFpEF and PH-HFpEF, will present data highlighting the use of levosimendan for the treatment of pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF)
    Presentation will occur at Technology and Heart Failure Therapeutics (THT-2024) – in Boston, MA, on March 6, 2024
    CHAPEL HILL, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced Dr. Sanjiv Shah, Stone Endowed Professor of Medicine, Director of Research for the Bluhm Cardiovascular Institute, and Director of the HFpEF Program at Northwestern University Feinberg School of Medicine, will present data and review the scientific basis for the use of levosimendan in PH-HFpEF.
  • Dr Shah’s presentation will occur during a scientific session focused on the treatment of pulmonary hypertension in patients with heart failure at the upcoming Cardiovascular Research Foundation’s Technology and Heart Failure Therapeutics (THT) Conference in Boston.

2024 IBS Awareness Month: The IBS Dilemma

Retrieved on: 
Thursday, March 7, 2024
Gastroenterology, Anxiety, Mental health, MD, Education, Diarrhea, Irritable bowel syndrome, Friends, Quality of life, Bloating, BMS, Defecation, Constipation, Habit, Face, Fear, International Foundation, Feinberg School of Medicine, IBS, Depression, Nursing

MOUNT PLEASANT, S.C., March 7, 2024 /PRNewswire/ -- Irritable bowel syndrome (IBS) affects up to 5-10% of individuals worldwide, making it one of the most common gastrointestinal disorders. Although IBS does not shorten a person's life span, living with IBS presents a myriad of challenges that can significantly impact one's quality of life. From navigating social situations to managing work responsibilities, individuals with IBS constantly face dilemmas that others may not fully comprehend. This April, for IBS Awareness Month, IFFGD highlights how crucial it is to shed light on the profound dilemmas and challenges individuals living with this often-misunderstood condition may face.

Key Points: 
  • This April, for IBS Awareness Month, IFFGD highlights how crucial it is to shed light on the profound dilemmas and challenges individuals living with this often-misunderstood condition may face.
  • This year, help IFFGD and the community raise awareness, promote understanding, and offer compassion to those living with IBS.
  • You can also join IFFGD's awareness campaign by sharing information from the IBS Awareness Month Media Toolkit .
  • Learn more about IBS, visit www.aboutIBS.org or www.youandibs.org to learn about IBS through and animated video series.

Which Test is Best? OB-GYN Lauren Streicher, M.D. Offers Expert Advice on Selecting Pregnancy Tests

Retrieved on: 
Tuesday, February 13, 2024
Other Consumer, Women, Seniors, Retail, Teens, Parenting, Baby, Maternity, Convenience Store, Family, Online Retail, Consumer, General Health, Other Retail, Health, Other Education, Supermarket, Specialty, Education, Urination, Feinberg School of Medicine, Urine, Birth, HCG, Gonadotropin, Digital, Pregnancy, Placenta, Confusion, Pregnancy test, Patient, Birth control

Lauren Streicher , M.D., OB-GYN, clinical professor at Northwestern University Feinberg School of Medicine, addresses the most common questions about purchasing pregnancy tests, providing expert insight on which test to choose.

Key Points: 
  • Lauren Streicher , M.D., OB-GYN, clinical professor at Northwestern University Feinberg School of Medicine, addresses the most common questions about purchasing pregnancy tests, providing expert insight on which test to choose.
  • “When speaking to patients, I find there is still a lot of confusion as to which at-home pregnancy test is right for them.
  • Whether actively trying to conceive or not, having access to accurate and reliable pregnancy tests can alleviate any uncertainties.”
    Dr. Streicher sheds light on the following considerations regarding purchasing at-home pregnancy tests:
    How do at-home pregnancy tests work?
  • Pregnancy tests detect human chorionic gonadotropin (hCG), the hormone produced by the placenta during pregnancy that is found in urine.

Inteleos Announces 2024 Board of Directors

Retrieved on: 
Friday, February 9, 2024
University of Colorado Hospital, Health, UCHealth, State College, Pennsylvania, Vein, Associate, Cardiac imaging, Feinberg School of Medicine, Business, Education, Oregon Institute of Technology

ROCKVILLE, Md., Feb. 09, 2024 (GLOBE NEWSWIRE) -- Inteleos, a non-profit global healthcare certification organization, today announced its Board of Directors.

Key Points: 
  • ROCKVILLE, Md., Feb. 09, 2024 (GLOBE NEWSWIRE) -- Inteleos, a non-profit global healthcare certification organization, today announced its Board of Directors.
  • Inteleos' new Board is composed of a diverse mix of leaders with deep experience in global healthcare, technology, business and finance.
  • “We are very pleased to welcome six current Board Members - some to new roles - as well as our newest board members, a few of whom have served Inteleos’ councils for some time,” said Inteleos CEO Dale Cyr.
  • “This stellar group of professionals are dedicated to the advancement of global quality patient care, lifelong learning and to the latest technological advances in medicine and business.”
    The new Board will leverage its expertise to help Inteleos advance its mission to fuel the global health community to ensure equitable access to quality care.

Sibel Announces its 4th FDA Clearance for Continuous Wearable Vital Signs Monitoring with ANNE® One and Additional Strategic Collaboration with Ann & Robert H. Lurie Children's Hospital of Chicago

Retrieved on: 
Wednesday, February 7, 2024
Continuity, Research institute, Hospital, Research, Patient, Adolescence, Temperature, Lurie Children's Hospital, FDA, Vital signs, ECG, Entrepreneurship, Food, Health, Premature, Disability, Assistant, Neurology, Feinberg School of Medicine, Oxygen saturation (medicine), IZotope, Pleasure, Digital health, Nursing

CHICAGO, Feb. 7, 2024 /PRNewswire/ -- Sibel Health, a leading digital health company, announced today that its continuous wearable monitoring solution, ANNE® One, has received another 510(k) clearance from the U.S. Food and Drug Administration (FDA). The ANNE® One platform now allows for continuous ambulatory ECG monitoring, SpO2, temperature, and non-invasive blood pressure measurements. In addition, this new clearance extends the population to include individuals 12 years and above for monitoring in the home and hospital settings.

Key Points: 
  • The ANNE® One platform now allows for continuous ambulatory ECG monitoring, SpO2, temperature, and non-invasive blood pressure measurements.
  • In addition, this new clearance extends the population to include individuals 12 years and above for monitoring in the home and hospital settings.
  • Steve Xu MD, Co-Founder and CEO of Sibel Health, said "Our mission here at Sibel Health is to deliver Better Health Data for All®.
  • Sibel Health also announces a new collaboration with Ann & Robert H. Lurie Children's Hospital of Chicago and its research enterprise, Stanley Manne Children's Research Institute.

Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™

Retrieved on: 
Wednesday, February 7, 2024
Traffic barrier, Sanfilippo, Genomics, Hearing, Growth, BBB, AFL, Metabolism, Feinberg School of Medicine, Spleen, Dermatan sulfate, Patient, Cerebrospinal fluid, University of North Carolina, FDA, Cognition, COMPASS, Mouse, CSF, Physician, Hunter syndrome, MPS II, Brain, Behavior, MPS, Mucopolysaccharidosis, Hunting, University, SGSH, ETV, Liver, Alfa, Glycogen storage disease, Pharmaceutical industry

Denali’s BBB-crossing enzyme replacement approach has the potential to prevent cognitive and behavioral manifestations in MPS IIIA.

Key Points: 
  • Denali’s BBB-crossing enzyme replacement approach has the potential to prevent cognitive and behavioral manifestations in MPS IIIA.
  • New two-year peripheral biomarker data demonstrate high magnitude and sustained reduction of urine heparan sulfate and dermatan sulfate, including in participants who switched from standard-of-care enzyme replacement therapy to tividenofusp alfa, suggesting enhanced peripheral activity.
  • Denali also announced that dosing has begun in the Phase 1/2 study of DNL126 for the potential treatment of MPS IIIA.
  • “Our goal is to bring effective new medicines to MPS families as soon as possible,” said Carole Ho, M.D., Chief Medical Officer of Denali.

Dr. Samuel Lin Continues Partnership With Haute Beauty Network

Retrieved on: 
Friday, February 2, 2024
Partnership, Northwestern University, Certification, AAPS, ABMS, Plastic surgery, Knowledge, Science, Bachelor, Feinberg School of Medicine, Rhinoplasty, Division, Medical specialty, Internet celebrity, Expert, Plastic and Reconstructive Surgery, Biomedicine, Mentorship, Literature, MD Anderson Cancer Center, Elective surgery, Honors colleges and programs, Medical education, Harvard University, Harvard Medical School, Physician, Northwestern Memorial Hospital, Breast surgery, Biomedical engineering, Cure, Pearl, Editorial, Associate, University, Student, Editor-in-chief, Dentistry

NEW YORK, Feb. 2, 2024 /PRNewswire-PRWeb/ -- Dr. Samuel Lin is a double board certified Plastic Surgeon and Associate Professor of Surgery at Harvard Medical School who practices in Boston, Massachusetts. Dr. Lin received his Bachelor's degree in Biomedical Engineering at Northwestern University and was enrolled in the Honors Program for Medical Education at Northwestern University, Feinberg School of Medicine, Chicago, Illinois. He then completed a five-year-residency in Otolaryngology-Head and Neck Surgery followed by a three-year-residency in Plastic and Reconstructive Surgery at Northwestern Memorial Hospital. This was followed by a one-year fellowship appointment in Microvascular Reconstructive Surgery at the world-renowned University of Texas M.D. Anderson Cancer Center in Houston, Texas. Throughout the course of his training, Dr. Lin gained state-of-the-art skills in a multitude of reconstructive and cosmetic procedures with his background in Head and Neck Surgery providing him with additional expertise in Plastic and Reconstructive Surgery. He has also been named a Top Influencer in #PlasticSurgery.

Key Points: 
  • Nose Expert from Boston, Dr. Samuel Lin, continues his partnership with Haute Beauty Network, now in his sixth year.
  • NEW YORK, Feb. 2, 2024 /PRNewswire-PRWeb/ -- Dr. Samuel Lin is a double board certified Plastic Surgeon and Associate Professor of Surgery at Harvard Medical School who practices in Boston, Massachusetts.
  • Dr. Lin is board certified by both the American Board of Plastic Surgery and the American Board of Otolaryngology-Head and Neck Surgery.
  • Dr. Lin, his team, and his collaborators regularly publish scientific papers in the literature to further knowledge about plastic surgery and other topics.